Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GENERICS NEWS IN BRIEF
October 12, 2009
- Teijin Pharma Pursues Synergism between Drugs and Homecare Business
October 12, 2009
- OPINION／Why Negatives Never Make a Positive
October 12, 2009
- BUSINESS NEWS IN BRIEF
October 12, 2009
- Korosho Proposes Distribution Scheme for Vaccines Made in Japan to Avoid Maldistribution
October 12, 2009
- TOPICS 2 articles
October 12, 2009
- Flu Vaccines to Be Imported from GSK, Novartis
October 12, 2009
- Japan's First DPP-4 Inhibitor Sitagliptin to Be Approved
October 12, 2009
- Gov't to Procure Flu Vaccines for 77 Million Persons
October 12, 2009
- Eisai Applies for Non-Erosive GERD in Japan as Additional Indication for Pariet
October 12, 2009
- SURVEY／20% of Respondents Reluctant to Receive New-Type Flu Vaccines
October 12, 2009
- Eisai, Abbott Japan Apply for Humira for Crohn's Disease
October 12, 2009
- SEMINAR／Patients' Awareness of RA Treatment Insufficient: Prof. Yamamoto
October 12, 2009
- Parliamentary Secretary Shinya Adachi to Evaluate Chuikyo Membership
October 12, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 12, 2009
- REGULATORY NEWS IN BRIEF
October 12, 2009
- Mediceo to Further Cut Distribution Costs
October 12, 2009
- Astellas Concentrates Drug Discovery Functions in Tsukuba
October 12, 2009
- Eisai Ties Up with DNDi for Chagas Disease
October 12, 2009
- New Antibody Drugs for Cancer Highlighted at JCA Annual Meeting
October 12, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…